To register and learn more, visit: PeerView.com/Portland26-Live For patients with hemophilia B who are accustomed to the demands of lifelong intravenous factor IX replacement therapy, advances with gene therapy represent a fundamental reimagining of what effective disease control could look like. However, numerous questions remain regarding the role of gene therapy within an expanding hemophilia treatment landscape and how to safely deliver care. Join PeerView for this CaseBook live symposium to hear our expert panel engage in dynamic case-based dialogue that illustrates the therapeutic impact of gene therapy in hemophilia B and offers care team clinicians strategies for implementing a collaborative, multimodal treatment model to overcome implementation barriers. Don�t miss this opportunity to gain real-world insights on evidence-based, patient-centered approaches to gene therapy in hemophilia B�register today to join us! Credits: CME: 1. 0 AMA PRA Category 1 CreditTM AAPA: 1 AAPA Category 1 CME credits IPCE: 1. 0 Interprofessional Continuing Education (IPCE) credit